{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"}],"units":"Participants"}],"description":"Specificity is defined as the number of non-diseased participants correctly classified divided by all non-diseased individuals. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true-negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Follow-up scans for up to one year can be used in analysis","groups":[{"description":"PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.\n\nGa-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.","id":"OG000","title":"Ga-68 Labeled PSMA-11 PET"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy","type":"PRIMARY","unitOfMeasure":"proportion of participants"}